Reversal Of Fortune For German Pharma As Bundesrat Supports Enhanced Drug Price Transparency
This article was originally published in The Pink Sheet Daily
Germany’s upper house of parliament, the Bundesrat, has decided after considerable wrangling that negotiated and discounted reimbursement prices of drugs sold in Europe’s biggest market will be made public, virtually ensuring that further price erosion will spread across the region.
You may also be interested in...
Drug makers in Germany say this year’s widely-referenced Pharmaceutical Prescribing Report contains misleading data and warn it will be used to suppress prices even further, stifling innovation and restricting patient access to drugs.
The updated German Pharmaceutical Act will ensure that drug prices negotiated there between pharmaceutical manufacturers and health insurers will remain hidden from public view, as Germany’s government seeks to avoid a pan-European drug price crash.
Changes to Germany’s drug reimbursement law have permitted Boehringer Ingelheim and Eli Lilly to submit an updated dossier for their oral therapy Trajenta, giving medicine makers who operate there hope that further positive amendments will occur.